Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy.
OBJECTIVE
Sorsby fundus dystrophy is a rare hereditary condition causing choroidal neovascularization leading to vision loss. Previously, treatment was mostly unsuccessful. Here, we analyze the result of various treatments administered over the years.


METHODS
Retrospective case-note review.


METHODS
Three adults from a Spanish family with Sorsby fundus dystrophy showed a very varied course. The untreated case was blind at presentation. Administration of photodynamic therapy and intravitreal anti-vascular endothelial growth factor agents managed to modify the history of disease, more successfully with the latter.


CONCLUSIONS
The intravitreal administration of anti-vascular endothelial growth factor agents seems to reduce the extent of scarring in Sorsby fundus dystrophy albeit without halting the episodic recurrences. This may lead to improved outcomes even when the visual acuity is compromised.
Department of Ophthalmology, "Hospital Clínic de Barcelona" University Hospital, Barcelona, Spain.
Johannes
J
Keller
Juan
J
Giralt
Socorro
S
Alforja
Ricardo P
RP
Casaroli-Marano
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000151:congenital / Q000188:drug therapy*; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab